TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03450629
Drug: Brimonidine Tartrate Ophthalmic Suspension
Normalized name: brimonidine tartrate Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PDP-716
Study: NCT03450629
Drug: Brimonidine Tartrate Ophthalmic Solution
Normalized name: Brimonidine Tartrate Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three Times Brimonidine Tartrate Ophthalmic Solution
Study: NCT01097551
Drug: Trinitrin
Normalized name: Trinitrine
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
Study: NCT04082260
Drug: Alemtuzumab Injection [Lemtrada]
Normalized name: alemtuzumab Injection [Lemtrada]
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days.
Study: NCT01097551
Drug: Neosynephrine 10% collyrium
DrugBank: Synephrine (DB09203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neosynephrine 10% collyrium: 2 drops
Study: NCT01187992
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/day
Study: NCT02093923
Drug: DX-2930
Normalized name: DX-890
DrugBank: Depelestat (DB17873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
Study: NCT01029509
Drug: OPB 31121
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
Study: NCT02305173
Drug: Intravenous Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
Study: NCT02305173
Drug: intravenous salin water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of the control group received homologated placebo 60 minutes before surgery.
Study: NCT01195116
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mcg/kg/hour
Study: NCT00105495
Drug: Ferriprox (deferiprone)
Normalized name: Ferriprox
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00105495
Drug: Desferal (deferoxamine)
Normalized name: deferoxamine Injection [Desferal]
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00269334
Drug: Using Citalopram(drug) or Paroxetine(drug)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02734524
Drug: Taxol
Normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 135-175mg/m2,q28d\*4
Study: NCT02734524
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=5,q28d\*4
Study: NCT03483883
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab IV 10 mg/kg every 2 weeks
Study: NCT03483883
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks
Study: NCT03230734
Drug: Radium-223
Normalized name: Radium-223
DrugBank: Radium Ra-223 (DB12813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
Study: NCT03230734
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
Study: NCT00825864
Drug: dexamethasone sodium phosphate 0.1% eye drops
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
Study: NCT00549302
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
Study: NCT00549302
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
Study: NCT00500318
Drug: Aclidinium Bromide
Normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium Bromide, 200μg. Once daily oral inhalation.
Study: NCT00098891
Drug: entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00098891
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00589914
Drug: RISPERDAL CONSTA
Normalized name: RisperDAL Consta
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
Study: NCT00589914
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
Study: NCT01204125
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study: NCT01204125
Drug: Iniparib (SAR2405550 -BSI-201)
Normalized name: Iniparib
DrugBank: Iniparib (DB13877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form : solution for infusion~Route of administration :Intravenous
Study: NCT00223938
Drug: sodium ferric gluconate
Normalized name: Sodium Ferric Gluconate Comp
DrugBank: Sodium ferric gluconate complex (DB09517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly intravenous injection Dose 1
Study: NCT00223938
Drug: sodium ferric gluconate
Normalized name: Sodium Ferric Gluconate Comp
DrugBank: Sodium ferric gluconate complex (DB09517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly intravenous injection Dose 2
Study: NCT03965624
Drug: Ninlaro
Normalized name: Ninlaro
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
Study: NCT00468871
Drug: fluocinolone acetonide intravitreal implant
Normalized name: Fluocinolone Acetonide Intravitreal Implant
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: surgical intravitreal implant of fluocinolone acetonide
Study: NCT00468871
Drug: corticosteroids and immunosuppressants
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic corticosteroids alone or combined with immunosuppressants
Study: NCT02574715
Drug: Levonorgestrel (Jaydess, BAY86-5028)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
Study: NCT02166853
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sedation with inhaled sevoflurane
Study: NCT02166853
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation with intravenous midazolam
Study: NCT00320853
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00945334
Drug: Neomycin
Normalized name: Neomycin
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg po bid for 14 days
Study: NCT00945334
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 550 mg po tid
Study: NCT01813435
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
Study: NCT01813435
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy
Study: NCT03662724
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
Study: NCT01497119
Drug: JNJ-39758979, 300 mg
DrugBank: JNJ-39758979 (DB18899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
Study: NCT02225106
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
Study: NCT02339415
Drug: Edoxaban 30mg daily
Normalized name: edoxaban 30 MG
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03701711
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Escalation~Patients in the dose escalation phase will receive oral treatment with:~Lenalidomide: 10, 15, or 25 mg on Days 1-21 of every 28-day cycle Dexamethasone: 20mg on Days 1,8,15 and 22~Starting doses of Lenalidomide will be assigned at the time of registration.~Dose Expansion~Once the MTD has been established or determined, 8 additional patients will be treated at the MTD of lenalidomide at the same schedule as above. Dexamethasone will be given at the same dose as in the dose escalation portion of the study.
Study: NCT00063830
Drug: Alicaforsen
Normalized name: Alicaforsen
DrugBank: Alicaforsen (DB06224)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01595841
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 mg po od loading dose for two days, then 2 mg po od for thirty days
Study: NCT00996424
Drug: Acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation with N-Acetylcysteine
Study: NCT02331498
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
Study: NCT02992457
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir 400 mg daily.
Study: NCT02992457
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin 1000-1200 mg daily
Study: NCT02992457
Drug: Pegylated-interferon alfa-2a
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a once weekly for 3 months
Study: NCT02992457
Drug: Simeprevir
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Olysio once daily.
Study: NCT02992457
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dakla once daily for three months.
Study: NCT02992457
Drug: Ritaprevir, paritaprevir, ombetasvir
DrugBank: Paritaprevir (DB09297)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Querevo for three months
Study: NCT02992457
Drug: Sofosbuvir and Ledipasvir
Normalized name: sofosbuvir and ledipasvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily for three months
Study: NCT00117182
Drug: Dry powder mannitol
Normalized name: mannitol Inhalation Powder
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03682640
Drug: Azithromycin Monohydrate
Normalized name: azithromycin monohydrate
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
Study: NCT00117182
Drug: Budesonide 400mcg administered via turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00117182
Drug: Ipratropium bromide 80mcg
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00117182
Drug: Salbutamol 400mcg
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03682640
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution for intravenous or subcutaneous use
Study: NCT02112552
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02112552
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IP
Study: NCT00964353
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
Study: NCT02252445
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol will be administered.
Study: NCT02252445
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane will be administered.
Study: NCT03546829
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mg, 4x daily for 5 weeks
Study: NCT02452346
Drug: Tosedostat
Normalized name: Tosedostat
DrugBank: Tosedostat (DB11781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg PO once daily continuously for each 28 day treatment cycle
Study: NCT01732250
Drug: Colistin
Normalized name: Colistin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
Study: NCT01732250
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
Study: NCT00108667
Drug: Talampanel
Normalized name: Talampanel
DrugBank: Talampanel (DB04982)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01411696
Drug: dexamethasone intravitreal implant 0.7 mg
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
Study: NCT00063258
Drug: Tarceva (OSI-774)
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg/day, starting day 1 and stopping night prior to surgery.
Study: NCT00063258
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Planned dose of 200 mg/m\^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
Study: NCT00063258
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
Study: NCT01561924
Drug: eptacog alfa (activated)
Normalized name: Eptacog alfa (activated)
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
Study: NCT03941834
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BHV3000 (rimegepant) 75mg tablet
Study: NCT01877694
Drug: Auriclosene Solution 0.3%
DrugBank: Auriclosene (DB12197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution dispensed as drops onto the eye
Study: NCT01877694
Drug: Auriclosene Vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Auriclosene (DB12197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Vehicle solution dispensed as drops onto the eye
Study: NCT00631007
Drug: Pioglitazone HCl
Normalized name: PIOGLITAZONE HCL
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-daily, oral
Study: NCT01235715
Drug: Evicel fibrin sealant
Normalized name: thrombin
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
Study: NCT03619876
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 125 MG/ML subcutaneous injections
Study: NCT03619876
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 Mg/0.8 mL Subcutaneous Kit
Study: NCT02994394
Drug: OPC-41061
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02638519
Drug: Hyperpolarized Xenon-129
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
Study: NCT00088049
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00088049
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01231373
Drug: polidocanol injectable foam, 0.125%
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active placebo for blinding
Study: NCT01509833
Drug: rFSH
Normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of rFSH for ovarian stimulation.
Study: NCT01509833
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
Study: NCT02172196
Drug: BI 10773
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01509833
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
Study: NCT02172196
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02328755
Drug: peg-IFN-α
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02328755
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.
Study: NCT03569540
Drug: Glibenclamide
Normalized name: Glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo-controlled; Double blind test